Bristol-Myers Squibb (BMY), Gladstone Enter Collaboration to ID Novel Targets in Alzheimer’s Disease
Tweet
Share
E-mailGet Alerts BMY Hot Sheet
Join SI Premium – FREE
Bristol-Myers Squibb Company (NYSE: BMY) and the Gladstone Institutes today announced the formation of a discovery-based research collaboration to identify and validate novel targets in Alzheimer’s disease.
Under the agreement, Bristol-Myers Squibb will fund Gladstone’s research efforts to identify targets that affect Tau dysfunction. Tau is a protein that binds the cell’s internal skeleton and may help regulate the activity of brain cells. In Alzheimer’s disease, Tau forms abnormal deposits called neurofibrillary tangles, a hallmark pathology of the disease. By identifying targets that prevent or reverse Tau dysfunction, Bristol-Myers Squibb and Gladstone hope to identify novel therapeutic strategies to modify the course of the disease.
Under the agreement, Bristol-Myers Squibb will fund Gladstone’s research efforts to identify targets that affect Tau dysfunction. Tau is a protein that binds the cell’s internal skeleton and may help regulate the activity of brain cells. In Alzheimer’s disease, Tau forms abnormal deposits called neurofibrillary tangles, a hallmark pathology of the disease. By identifying targets that prevent or reverse Tau dysfunction, Bristol-Myers Squibb and Gladstone hope to identify novel therapeutic strategies to modify the course of the disease.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Reiterates Buy Rating on Bristol-Myers Squibb Co. (BMY)
- Nuvectis Pharma (NVCT) files $200M mixed shelf
- Gray Media closes $750M note offering to refinance higher-rate debt
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
